Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

INTRODUCTION: Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients wit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Dermatol Ther (Heidelb)
Glavni autori: Armstrong, April, Paul, Carle, Puig, Luis, Boehncke, Wolf Henning, Freeman, Michael, Torii, Hideshi, Papp, Kim, Griffiths, Christopher E. M., Blauvelt, Andrew, Reich, Kristian, Gooderham, Melinda, Terui, Tadashi, Renda, Lisa, Agada, Noah, Xu, Wen, Gallo, Gaia, Lebwohl, Mark G.
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2019
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994584/
https://ncbi.nlm.nih.gov/pubmed/31749092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-019-00340-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items